Abstracts tagged "Myositis"

Abstract Number: 0699 • ACR Convergence 2021
Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
Lilian Vilar, William Moore and Ian Ward, Dwight D Eisenhower Army Medical Center, Fort Gordon
Background/Purpose: The Idiopathic Inflammatory myopathies (IIM) are characterized by muscle damage and progressive weakness. Myoglobin is not typically released in high levels in IIM and…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 0957 • ACR Convergence 2020
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
Bhargavi Duvvuri¹, Lauren Pachman², Richard Moore¹, Stephen Doty³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, ³The Hospital for Special Surgery, New York
Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
Abstract Number: 1074 • ACR Convergence 2020
A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine
Karel Venne¹, Valérie Leclair², Julie D'Aoust¹, Océane Landon-Cardinal³, Alexandra Albert⁴, Julie Beauchemin⁵, Denis Brunet⁶, Lucie Roy⁷, Benjamin Ellezam⁸, Jason Karamchandani⁹, Rami Massie¹⁰, Erin O'Ferrall¹⁰, Alain Meyer¹¹, Yves Troyanov¹², Minoru Satoh¹³, Marvin Fritzler¹⁴ and Marie Hudson², ¹Division of Rheumatology, Rheumatology Fellow, McGill University,, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁵Division of Rheumatology, Hôpital Charles-Lemoyne, Longueuil, QC, Canada, ⁶Division of Neurology, Centre Hospitalier de l’Université Laval, Quebec, QC, Canada, ⁷Division of Rheumatology, CIUSSS du Saguenay Lac-Saint-Jean, Saguenay, Canada, ⁸Division of Pathology, CHU Sainte-Justine, Montreal, QC, Canada, ⁹Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹⁰Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹¹Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ¹³Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc). There is a paucity of data on scleromyositis…
Abstract Number: 1095 • ACR Convergence 2020
Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience
Khalil Bourji¹, Christopher Mecoli², Julie Paik³, Jemima Albayda³, Eleni Tiniakou³, William Kelly³, Thomas E Lloyd³, Andrew Mammen⁴ and Lisa Christopher-Stine³, ¹Wayne State University/Henry Ford Hospital, Dearborn, MI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴NIH, Bethesda, MD
Background/Purpose: To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated…
Abstract Number: 0959 • ACR Convergence 2020
Altered Gut Microbiome in Dermatomyositis
Sangmee Bae¹, Tien Dong², Venu Lagishetty³, William Katzka⁴, Jonathan Jacobs³ and Christina Charles-Schoeman⁵, ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, ⁴UCLA, Los Angeles, ⁵University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy associated with marked microvascular dysfunction and high morbidity and mortality. The gut microbiome has been implicated in the…
Abstract Number: 1075 • ACR Convergence 2020
Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study
Sandeepkumar Gupta¹, Debendra Pattanaik², Tulio Bertorini² and Amado Afreire³, ¹Medical College Of Georgia at Augusta University Medical Center, Augusta, GA, ²University of Tennessee Health Science Center, Memphis, TN, ³University of Tennessee Health Science Cente, Memphis, TN
Background/Purpose: Myositis specific and associated autoantibodies are now being used more frequently in the diagnosis of idiopathic inflammatory myositis. However there is a no study…
Abstract Number: 1096 • ACR Convergence 2020
Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
Jammie Law¹, Ana Valle², Katherine Mullins³ and Shereen Mahmood⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…
Abstract Number: 1055 • ACR Convergence 2020
Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression
Erin Wilfong¹, Gabriel Schroeder¹, April Barnado¹, Steven Lord¹, Narender Annapureddy¹, Rosemarie Dudenhofer¹ and Leslie J. Crofford¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Classification criteria for interstitial pneumonia with autoimmune features (IPAF) were introduced in 2015 to identify interstitial lung disease (ILD) patients who might benefit from…
Abstract Number: 1076 • ACR Convergence 2020
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Lois Bolko¹, Kevin Didier², Jean-Hugues Salmon¹, Makoto Miyara³, Segolene Toquet², Amelie Servettaz², Yves Allenbach³, Olivier Benveniste⁴ and Baptiste Hervier⁵, ¹Maison Blanche Hospital, Reims, Champagne-Ardenne, France, ²Robert Debre Hospital, Reims, Champagne-Ardenne, France, ³Sorbonne Université, Paris, Ile-de-France, France, ⁴Sorbonne Université, paris, France, ⁵Saint-Louis Hospital, Paris, Ile-de-France, France
Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
Abstract Number: 1056 • ACR Convergence 2020
Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement
Mohamed Alalwani¹, Bassam Alhaddad², Basem Zraik³, Christopher O'Rourke³, Ruchi Yadav³, Ali Askari¹, Charles Malemud¹ and Soumya Chatterjee⁴, ¹Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Westlake, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Richmond Heights, OH
Background/Purpose: To evaluate the patterns, severity and, prognostic parameters of interstitial lung disease (ILD) in Anti Jo1 Syndrome (AJS).Methods: We identified 51 anti-Jo-1 patients with…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
Abstract Number: 1099 • ACR Convergence 2020
High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Validation of Observations from the MyoCite Dataset
Rudrarpan Chatterjee¹, Pankti Mehta², Vikas Agarwal¹ and Latika Gupta², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections are a major cause of morbidity and mortality in idiopathic inflammatory myopathy (IIM), more so in India.[1-3] The objective of this study was…
Abstract Number: 1057 • ACR Convergence 2020
Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts
Alexander Oldroyd¹, Paul New², Janine Lamb¹, William Ollier¹, Robert Cooper², Kuberacka Mariampillai³, Olivier Benveniste³, Jiří Vencovský⁴, Heřman Mann⁵, Zoltan Griger⁶, Melinda Nagy-Vincze⁶, Katalin Dankó⁶ and Hector Chinoy⁷, ¹University of Manchester, Manchester, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³Sorbonne Université, Paris, France, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶University of Debrecen, Debrecen, Hungary, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are strongly associated with the development of clinically detectable cancer. Cancer screening has therefore been advocated in newly diagnosed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].